Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$9.77
▼ $0.05 (-0.5%)
Market data updated: 09/25 11:57 PM
Fundamentals updated: 09/25/2026
News analyzed: 09/25/2026
Market Cap
$504.33M
Day Range
$9.65 - $9.90
52-Week Range
$4.58 - $9.98
Beta
—
Next Earnings
04.11.2026
Support
$7.41
Resistance
$9.98
PBYI is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+107.9% (1Y)
Strengths: 19/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $12.42 vs. price $9.77 (+27.2%)
Fair Value
Biggest negative driver
Daily volatility (ATR)
ATR: 4.1% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
68
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
21d ago · $9.41
Evidence: -3.9pp vs. sector average today
What happened after
21d ago · $9.41
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
21d ago · $9.41
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 29, 2026
Then
72
$9.06
Now
68
$9.77
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
42
Quality
63
Value
62
Momentum
80
Risk
54
Sentiment
80
Fundamental
77
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Puma Biotechnology Inc. has centered on its financial performance and strategic developments. The company reported a strong Q2 2026 earnings beat, with raised guidance, while analysts like TD Cowen adjusted their price targets upward to $6. Additionally, there was focus on its revenue stream from NERLYNX, a potential second oncology franchise, alongside ongoing discussions about inducement awards under Nasdaq listing rules. Investor sentiment appears cautiously optimistic.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Puma Biotechnology Inc. News trend score: 80. Reason: 5 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
35
🎯 Conviction (vs. Emotion)
42
Psychology
57
Fundamentals
77
Technical
80
Valuation
62
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+20%
Market Narrative
53
Fundamental Reality
42
Narrative Gap
+11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
PBYI’s psychology is dominated by anchoring (49), where traders appear fixated on the 2.5% resistance gap, despite moderate euphoria (31) and herding (38) signals. The narrative-reality gap (+14) and overvaluation (-24% vs. DCF) may reinforce selective optimism, while FOMO (33) is muted by RSI (61) and volume not exceeding 1.04x. The key question: will traders break from anchoring if resistance holds, or will momentum sustain euphoria despite valuation concerns?
Updated: 09/08/2026, 10:23 PM
What could change this?
👥 What the crowd believes
"PBYI Q2 earnings & sales beat estimates, 2026 guidance raised"
"Debt-Free Status and Raised guidance"
"TD Cowen raises price target from $5 to $6"
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 80/100
🔴 Weakest match
Samuel Armstrong Nelson — 13/100
🗣️ Why do they disagree?
The stark divide in verdicts for PBYI reflects deep methodological disagreements about risk, valuation, and market psychology. Walter Bagehot’s high score and bullish liquidity assessment contrast sharply with Samuel Armstrong Nelson’s bearish cycle warning, illustrating a tension between structural resilience and speculative overvaluation. Meanwhile, growth-oriented investors like Thorstein Veblen and Benjamin Graham (regular) see potential, while value-focused strategists like Philip Fisher and Peter Lynch dismiss it outright, highlighting a clash between qualitative business merit and quantitative price thresholds. Even within the same investor’s frameworks—like Howard Marks’ mixed verdicts—expectations and market timing create further polarization, suggesting this stock is a battleground between contrarians and those wary of crowd-driven momentum.
Walter Bagehot
Lombard Street (1873)
🟢 80
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 69
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 58
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 58
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 51
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 48
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 47
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 40
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 37
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 33
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 27
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 23
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 13
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
74.5%
Operating Margin
16.3%
Net Margin
13.6%
EBITDA Margin
21.1%
ROE
23.9%
ROA
14.4%
ROIC
—
EPS
$0.62
Cash
$29.64M
Total Debt
$22.52M
Current Ratio
2.00
Debt/Equity
0.17
How is Fair Value calculated? →
Current Price
$9.77
Estimated Fair Value (DCF)
$12.42
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+27.2%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
0.1%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 0.1% | $41.76M | $38.31M |
| 2 | 0.7% | $42.05M | $35.39M |
| 3 | 1.3% | $42.59M | $32.89M |
| 4 | 1.9% | $43.40M | $30.74M |
| 5 | 2.5% | $44.48M | $28.91M |
Base FCF (last actual year)
$41.73M
Terminal Value
$701.45M
Present Value of Terminal Value
$455.89M
Enterprise Value
$622.14M
Net Debt
$-7.11M
Equity Value
$629.25M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.57
Tangible Book Value per Share (Tangible NAV)
$1.76
Sentiment based on basic keywords (not AI) — 5 positive, 15 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 9.9.2026
Business Wire · 9.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
SeekingAlpha · 8.9.2026
Yahoo · 3.9.2026
Business Wire · 3.9.2026
Motley Fool · 14.8.2026
Zacks · 12.8.2026
SeekingAlpha · 10.8.2026
Zacks · 7.8.2026
Benzinga · 7.8.2026
Moby · 7.8.2026
SeekingAlpha · 7.8.2026
MarketBeat · 7.8.2026
GuruFocus.com · 7.8.2026
Zacks · 6.8.2026
Puma Biotechnology Inc (PBYI) currently has a StockIQ AI score of 68/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PBYI currently scores 68/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PBYI's estimated fair value is $12.42, which is 27.2% above the current price of $9.77. This is one valuation model among several signals in the fair-value category, not a price target.
PBYI's technical score is 80/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $12.42 vs. price $9.77 (+27.2%); Operating margin is stable or improving over time; Return on equity (ROE): 23.9% — strong.
Based on the real signals StockIQ computed: ATR: 4.1% of price; Revenue growth (last year): -0.9%; Earnings per share (EPS) growth: -1.6%.
StockIQ has no recorded dividend payment history for PBYI.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 18 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Cesano Alessandra | Open Market Sale | 14.9.2026 | 56,700 | -62,150 | $9.12 |
| WILSON TROY EDWARD | Open Market Sale | 14.9.2026 | 54,750 | -5,000 | $9.10 |
| Cesano Alessandra | Exercise of Derivative Securities | 14.9.2026 | 118,850 | +50,000 | $2.93 |
| Cesano Alessandra | Exercise of Derivative Securities | 14.9.2026 | 50,000 | -50,000 | — |
| HUNT DOUGLAS M | Open Market Sale | 6.7.2026 | 8,460 | -8,460 | $8.26 |
| NOUGUES MAXIMO F | Open Market Sale | 6.7.2026 | 9,386 | -9,386 | $8.26 |
| AUERBACH ALAN H | Open Market Sale | 6.7.2026 | 44,058 | -44,058 | $8.26 |
| AUERBACH ALAN H | Open Market Sale | 6.7.2026 | 7,261,671 | -44,058 | $8.26 |
| NOUGUES MAXIMO F | Open Market Sale | 6.7.2026 | 230,637 | -9,386 | $8.26 |
| HUNT DOUGLAS M | Open Market Sale | 6.7.2026 | 196,841 | -8,460 | $8.26 |
| Stuglik Brian M | Open Market Sale | 12.6.2026 | 8,100 | -8,100 | $7.20 |
| Dorval Allison | Open Market Sale | 12.6.2026 | 11,610 | -11,610 | $7.20 |
| MOYES JAY M | Open Market Sale | 12.6.2026 | 22,000 | -22,000 | $7.22 |
| Senderowicz Adrian | Open Market Sale | 12.6.2026 | 27,000 | -27,000 | $7.20 |
| WILSON TROY EDWARD | Open Market Sale | 12.6.2026 | 10,800 | -10,800 | $7.20 |
| MOYES JAY M | Open Market Sale | 12.6.2026 | 58,322 | -22,000 | $7.22 |
| Dorval Allison | Open Market Sale | 12.6.2026 | 90,780 | -11,610 | $7.20 |
| Senderowicz Adrian | Open Market Sale | 12.6.2026 | 27,000 | -27,000 | $7.20 |
| Stuglik Brian M | Open Market Sale | 12.6.2026 | 113,858 | -8,100 | $7.20 |
| WILSON TROY EDWARD | Open Market Sale | 12.6.2026 | 59,750 | -10,800 | $7.20 |
| Stuglik Brian M | Grant/Award from Employer | 11.6.2026 | 27,000 | +27,000 | — |
| Cesano Alessandra | Grant/Award from Employer | 11.6.2026 | 27,000 | +27,000 | — |
| MOYES JAY M | Grant/Award from Employer | 11.6.2026 | 27,000 | +27,000 | — |
| WILSON TROY EDWARD | Grant/Award from Employer | 11.6.2026 | 27,000 | +27,000 | — |
| MILLER MICHAEL PATRICK | Grant/Award from Employer | 11.6.2026 | 27,000 | +27,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,319,663 shares short as of 2026-09-15 · vs. 4,274,524 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
67.1% of trading volume this week was short selling, vs. 55.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology